-
Product Insights
NewDystonia – Drugs In Development, 2024
Empower your strategies with our Dystonia – Drugs In Development, 2024 report and make more profitable business decisions. Dystonia is a neurological hyperkinetic movement disorder in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures. Dystonia is often intensified or exacerbated by physical activity, and symptoms may progress into adjacent muscles The Dystonia drugs in development market research report provide comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage...
-
Product Insights
NewSpasmodic Torticollis (Cervical Dystonia) – Drugs In Development, 2024
Empower your strategies with our Spasmodic Torticollis (Cervical Dystonia) – Drugs In Development, 2024 report and make more profitable business decisions. Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head The Spasmodic Torticollis (Cervical Dystonia) drugs in development...
-
Product Insights
NewSchizophrenia – Drugs In Development, 2024
Empower your strategies with our Schizophrenia – Drugs In Development, 2024 report and make more profitable business decisions. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia drugs in development market research report provide comprehensive information on the therapeutics under development for Schizophrenia, complete with...
-
Product Insights
NewBlepharospasm – Drugs In Development, 2024
Empower your strategies with our Blepharospasm – Drugs In Development, 2024 report and make more profitable business decisions. Blepharospasm is involuntary eyelid movements like blinking or twitching. It is caused due to abnormalities in an area of the brain that impacts muscle movement. Symptoms include uncontrollable blink, squint, wink, twitch, or squeezing closed one or both eyes. Diagnosis relies on physical examination, medical history, and ruling out other possible causes. Treatment for blepharospasm can include stress management, botulinum type A toxin...
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dipraglurant IR in Blepharospasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dipraglurant IR in Blepharospasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dipraglurant IR in BlepharospasmDrug Details:Dipraglurant IR (ADX-48621) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maplirpacept in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Refractory Multiple MyelomaDrug Details:Maplirpacept (TTI-622) is under development for the...
-
Company Profile
Addex Therapeutics Ltd – Company Profile
Addex Therapeutics Ltd (Addex) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson's disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction,...
Add to Basket -
Product Insights
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Metabotropic Glutamate Receptor 4 (GRM4) Drugs in Development Report Overview Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. The Metabotropic Glutamate Receptor 4 (GRM4) drugs in development research report provides comprehensive information on the therapeutics under development for GRM4. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication. The pipeline report covers the descriptive pharmacological action and product description of GRM4. It includes...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – dipraglurant ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry dipraglurant ER Drug Details Dipraglurant extended-release formulation is under development as an adjunctive treatment...